ITP facts Flashcards
M:F in ITP
Females of child baring age
M:F 1:1 for age 60
Serious bleeding in ITP
5-6%
Anti-GP ab in ITP
specific but not sensitive
good for confirmation but cannot distinguish primary and secondary
Phases of ITP
< 3 months - newly diagnosed
3-12 months- persistent
>12 months- chronic
Occult cerebral microbleeds in ITP %
50%
in pts with PLT<30
Rituximab addition in 1st line in ITP
better sustained response rates
but no benefit in ORR in 1 year
not recommended
2nd line options for ITP
Rituximab
TPO-RA
Fosfamatinib
3rd line option for ITP
Splenectomy
Persistent/Chronic ITP %
60-70%
TPO-RA ORR in ITP
85%
Rituximab ORR in ITP
60-70%
achieved after 4-8 weeks
most will relapse after 6 months
Fostamatinib ORR in ITP
40%
with durable response
Splenectomy in ITP ORR
60-70%
long term durable response rates
usually 3rd/4th line
at least 12-24 months after diagnosis
Novel therapies in ITP
Rozanolixizumab
Efgartigimod
Sutimlimab
BTKi
Platelet counts for delivery
50K vaginal
70k CS
80K for epidural anesthesia